No Data
Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH): The crystal eye artificial lens has been approved for listing through the special review procedure for Innovative Medical Management.
On January 7, Gelonghui reported that Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH) announced that its "artificial crystalline lens for phakic eyes" has recently been approved for registration by the National Medical Products Administration through a special review for Innovative Medical Management medical instruments. The artificial crystalline lens for phakic eyes is a refractive artificial lens, and this product is based on innovative balanced acrylic material, featuring a zero spherical aberration design with a large optical zone and a double concave stabilizing arch height design. Once implanted in the eye, it can serve as a refractive component, effectively reducing/correcting myopia and providing patients with high-quality postoperative visual acuity.
Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH): The plan for the Chairman and some Directors and senior management to increase their shareholding in the company has been completed.
Gelonghui reported on December 23 that Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH) announced that from June 20, 2024, to December 20, 2024, the company's controlling shareholder, actual controller, Chairman and General Manager Mr. Xie Jiangbing, Director and senior management Ms. Wang Zhao, and senior management Mr. Jia Baoshan cumulatively increased their shareholding in the company by 45,109 shares through the centralized bidding trading method via the Shanghai Exchange, accounting for 0.0238% of the company's current total equity, with a total increase amount of 3.4366 million yuan (excluding stamp duty, transaction commission, and other trading costs), which has surpassed this increase.
Shareholder Bai Ying of eyebright medical technology (beijing) co., ltd. (688050.SH) intends to reduce shareholding by no more than 1.5%.
Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH) announced that shareholder Bai Ying, who holds 5.63% of the shares, plans to conduct a block trade...
688050 Aibo Healthcare 2024 Third Quarter Report
eyebright medical technology (beijing) co., ltd. (688050.SH): The net income for the first three quarters was 0.318 billion yuan, a year-on-year increase of 26.04%.
EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD. (688050.SH) announced on October 29th that in the first three quarters of 2024, it achieved a total operating income of 1.075 billion yuan, a year-on-year increase of 60.94%; net income attributable to shareholders of the parent company was 0.318 billion yuan, a year-on-year increase of 26.04%; and the basic earnings per share was 1.68 yuan.
Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH): It is planned to raise funds by no more than 0.3 billion yuan through a private placement.
Gelonghui October 29th, eyebright medical technology (beijing) co., ltd. (688050.SH) announced the stock issuance plan for 2024 to specific entities through a simple process. The total amount of funds raised through this simple process for issuing stocks will not exceed 300 million yuan (including the base amount). The net funds raised after deducting issuance expenses will be used for the following projects: the construction project of contact lenses and injection molding production line, and supplementary working capital.
No Data
